Corporate sustainability leaders spoke about innovation and partnering with the public sector during a panel at the inaugural ...

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...

很快，另一家跨国医药巨头GSK入局。 2019年2月12日，Merck与GSK宣布，双方达成全球战略合作联盟，共同负责M7824在全球范围内的临床开发及商业推广。 在此次合作中，默克可从GSK获得3亿欧元首付款、5亿欧元研发里程碑付款，以及在未来产品上市后29亿欧元的商业 ...

Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531.

Sanofi has received two separate bids from private equity firms for its consumer health unit, which could be valued at 15 ...

GSK PLC GSK shares inched up 0.20% to £15.31 Tuesday, on what proved to be an all-around favorable trading session for the ...

（吉隆坡24日讯）葛兰素史克制药有限公司（GSK）宣布，Arexvy 疫苗（MAL24086007ARZ）已在马来西亚获得批准用于治疗呼吸道合胞病毒（RSV）。RSV是一种常见的呼吸道病毒，可引起下呼吸道疾病（LRTD）和老年人肺炎等严重的临床影响。马拉工艺大学苏丹阿都拉教学医院副院长兼呼吸内科顾问阿末依祖亚努丁表示，RSV可能会造成严重影响，尤其是对患有哮喘、慢性阻塞性肺病（COPD）和慢性心力 ...

If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis ...

The "Typhoid Fever - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.Comprehensive insights into the future of typhoid fever treatment are now available, exploring ...

Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine ...

A groundbreaking study will investigate Parkinson’s disease in unprecedented detail, with the aim of discovering a cure for ...